Toxin-Mediated siRNA Delivery

Spencer Zhao; Jeffrey M Karp; Nitin Joshi

doi:10.1016/j.tips.2020.06.006

Toxin-Mediated siRNA Delivery

Trends Pharmacol Sci. 2020 Aug;41(8):511-513. doi: 10.1016/j.tips.2020.06.006. Epub 2020 Jun 30.

Authors

Spencer Zhao¹, Jeffrey M Karp², Nitin Joshi³

Affiliations

¹ Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
² Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: [email protected].
³ Center for Nanomedicine and Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address: [email protected].

PMID: 32620268
DOI: 10.1016/j.tips.2020.06.006

Abstract

AB toxins with built-in cell targeting and endosomal escape mechanisms are attractive intracellular delivery vehicles. However, their compatibility with nucleic-acid-based therapeutics is not fully explored. Arnold et al. demonstrated the first functional siRNA delivery by diphtheria toxin (DT) in vitro, marking an important step in expanding the utility of AB toxins for nucleic acid delivery.

Keywords: diphtheria toxin; glioblastoma; siRNA delivery.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Diphtheria Toxin* / metabolism
Endosomes* / metabolism
Protein Transport
RNA, Small Interfering / metabolism

Substances

Diphtheria Toxin
RNA, Small Interfering